Group 1 - The core point of the article is that Changying Precision (300115) announced a stock option incentive plan for 2025, granting 14.262 million stock options to 870 eligible recipients, amidst concerns about potential arbitrage by executives who disclosed a share reduction plan shortly before participating in an employee stock ownership plan [2][3][5] - The company operates in the electronic components sector, focusing on electromagnetic shielding components, precision connectors, and parts for humanoid robots, with its stock price having doubled since early 2025 [3] - The stock reduction plan was disclosed on December 17, 2025, with five executives planning to sell a total of 132,300 shares, citing personal financial needs [4][5] Group 2 - The employee stock ownership plan allows executives to purchase shares at a significant discount, with the purchase price set at 20.56 yuan per share, compared to a market price around 40 yuan, raising questions about potential "high sell, low buy" practices [7][8] - Legal experts noted that while the actions of the executives are technically compliant with existing regulations, they may create a perception of unfairness in the market, suggesting a need for regulatory improvements to address potential arbitrage opportunities [8][10] - The current regulatory framework lacks clear restrictions on executives participating in employee stock ownership plans during share reduction windows, which could lead to exploitation of this "gray area" [10]

Core Viewpoint - Changying Precision (300115) announced a stock option incentive plan on January 23, 2025, granting 14.262 million stock options to 870 eligible recipients, raising concerns about potential "high sell low buy" arbitrage practices among executives [2][3] Group 1: Stock Option Incentive Plan - The stock option incentive plan is set to be effective on the announcement date, with a total of 14.262 million options to be granted [2] - The company has previously attracted market attention due to a smaller employee stock ownership plan involving executives who disclosed a reduction plan shortly before participating in the stock ownership plan [2][3] Group 2: Executive Share Reduction Plans - Five executives disclosed a share reduction plan on December 17, 2025, with the total shares to be reduced amounting to 382,528 shares, representing approximately 0.0280% of the total shares after deducting repurchased shares [4][5] - The reasons for the share reductions were cited as personal funding needs, with the shares sourced from stock incentives or secondary market purchases [5] Group 3: Employee Stock Ownership Plan - The employee stock ownership plan draft includes participation from 31 individuals, with significant shares allocated to executives, including 3.248 million shares for the general manager [6] - The shares in the employee stock ownership plan are sourced from repurchased shares at an average price of 34.27 yuan per share, while the purchase price for employees is set at 20.56 yuan per share, approximately 60% of the repurchase average [7] Group 4: Legal and Regulatory Concerns - Legal experts noted that while the actions of the executives are formally compliant with existing regulations, there are concerns regarding the fairness of the practices, as they create an arbitrage opportunity [8][9] - The current regulatory framework lacks clear restrictions on executives participating in employee stock ownership plans during share reduction windows, which could lead to potential exploitation of regulatory gray areas [10]

（记者 曾健辉） 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 每经AI快讯，长盈精密1月23日晚间发布公告称，公司第六届第三十二次董事会会议于2026年1月23日 以通讯方式召开。会议审议了《关于豁免提前三天发出董事会通知的议案》等文件。 ...

深圳市长盈精密技术股份有限公司 （5）法律法规规定不得参与上市公司股权激励的； 董事会薪酬与考核委员会关于 2025 年股票期权激励计划 授予激励对象名单（授予日）的核查意见 深圳市长盈精密技术股份有限公司（以下简称"公司"）于 2026 年 1 月 23 日 召开第六届董事会第三十二次会议，审议通过了关于向 2025 年股票期权激励计 划激励对象授予股票期权的议案。根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司股权激励管理办法》等法律法规和《公司章程》有关规 定，董事会薪酬与考核委员会对公司 2025 年股票期权激励计划授予激励对象名 单（授予日）进行了核查，现发表核查意见如下： 1、公司不存在《上市公司股权激励管理办法》等法律、法规及规范性文件 规定的禁止实施股权激励计划的情形，公司具备实施股权激励计划的主体资格。 公司本次激励计划授予激励对象具备《中华人民共和国公司法》等法律、法规及 规范性文件和《公司章程》规定的任职资格，符合《深圳证券交易所创业板股票 上市规则》规定的激励对象条件，符合公司本次激励计划规定的激励对象范围， 其作为公司本次激励计划授予的激励对象的主体资格合法、有效。 ...

法律意见书 广东华商律师事务所 关于深圳市长盈精密技术股份有限公司 2025 年股票期权激励计划授予事项的 法律意见书 广东省深圳市福田区深南大道 4011 号港中旅大厦第 21A、22A、23A、24A、25A、26A 层 21A, 22A, 23A, 24A, 25A, 26A /F, HKCTS Tower, 4011 Shennan Road, Futian District, Shenzhen, PRC 邮政编码（P.C.）：518048 电话（Tel）：0755-83025555 传真（Fax）：0755-83025068 网址：http://www.huashanglawyer.com 法律意见书 释 义 注：本法律意见书中若出现总数合计与各分项数值之和存在尾数不符的，系 四舍五入原因造成。 本法律意见书中，除非文义另有所指，下列词语或简称具有如下含义： 长盈精密/公司/上市 公司 指 深圳市长盈精密技术股份有限公司 《激励计划（草案）》 指 《深圳市长盈精密技术股份有限公司 2025 年股票 期权激励计划（草案）》 《 实 施 考 核 管 理 办 法》 指 《深圳市长盈精密技术股份有限公司 2 ...

证券代码：300115 证券简称：长盈精密 公告编号：2026-06 深圳市长盈精密技术股份有限公司 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 关于向 2025 年股票期权激励计划激励对象授予股票期权的公告 重要内容提示： 1、股票期权授予日：2026 年 1 月 23 日 2、股票期权授予数量：1,426.20 万份 3、股票期权行权价格：36.47 元/股 深圳市长盈精密技术股份有限公司(以下简称"公司")2025 年股票期权激励计划（以下简 称"本次激励计划"）规定的期权授予条件已经成就，根据公司 2026 年第一次临时股东会的 授权，公司于 2026 年 1 月 23 日召开第六届董事会第三十二次会议，审议通过了关于向 2025 年股票期权激励计划激励对象授予股票期权的议案，同意以 2026 年 1 月 23 日为授予日，向 符合条件的 870 名激励对象授予 1,426.20 万份股票期权。现将相关事项公告如下： 一、本次激励计划简述及已履行的审批程序 1、本次激励计划简述 （1）股票来源：公司向激励对象定向发行的公司 A 股普通股股票。 （2）授予 ...

一、董事会会议召开情况 证券代码：300115 证券简称：长盈精密 公告编号：2026-05 深圳市长盈精密技术股份有限公司 第六届董事会第三十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、审议通过了关于向 2025 年股票期权激励计划激励对象授予股票期权的议 案 根据《上市公司股权激励管理办法》《公司 2025 年股票期权激励计划(草案)》 的相关规定，董事会认为公司和激励对象已满足本次股票期权激励计划规定的各 项授予条件。根据公司 2026 年第一次临时股东会的授权，董事会确定本次激励计 划的授予日为 2026 年 1 月 23 日，同意向符合条件的 870 名激励对象授予 1,426.20 万份股票期权。具体内容详见公司披露在巨潮资讯网《关于向 2025 年股票期权激 励计划激励对象授予股票期权的公告》。 1、会议通知的时间和方式：深圳市长盈精密技术股份有限公司（以下简称"公 司"）第六届董事会第三十二次会议（以下简称"本次会议"）通知于 2026 年 1 月 23 日以书面方式向全体董事发出。 2、会议召开的时间、地点和方式：本次会议 ...

（编辑 任世碧） 证券日报网讯 1月22日，长盈精密发布2025年度业绩预告称，公司预计2025年度归属于上市公司股东的 净利润为54，500万元至63，500万元，比上年同期下降29.36%至17.70%。 ...

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

长盈精密1月22日公告，预计2025年归母净利润54,500万元～63,500万元，同比下降29.36%～17.70%。 公司归属于上市公司股东的净利润下降的主要原因为去年同期处置子公司股份有较高的非经常性收益， 本年度无此事项收益。 ...